395 related articles for article (PubMed ID: 33333233)
1. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE).
Möckel T; Basta F; Weinmann-Menke J; Schwarting A
Autoimmun Rev; 2021 Feb; 20(2):102736. PubMed ID: 33333233
[TBL] [Abstract][Full Text] [Related]
2. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.
Vincent FB; Saulep-Easton D; Figgett WA; Fairfax KA; Mackay F
Cytokine Growth Factor Rev; 2013 Jun; 24(3):203-15. PubMed ID: 23684423
[TBL] [Abstract][Full Text] [Related]
3. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
4. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
5. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus.
Spinelli FR; Barbati C; Cecarelli F; Morello F; Colasanti T; Vomero M; Massaro L; Orefice V; Alessandri C; Valesini G; Conti F
Arthritis Res Ther; 2019 Nov; 21(1):245. PubMed ID: 31752963
[TBL] [Abstract][Full Text] [Related]
7. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
Sanchez-Niño MD; Ortiz A
Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
[TBL] [Abstract][Full Text] [Related]
8. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
9. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
11. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
[TBL] [Abstract][Full Text] [Related]
12. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus.
Saidoune F; Even G; Lamri Y; Chezel J; Gaston AT; Escoubet B; Papo T; Charles N; Nicoletti A; Sacre K
Arthritis Rheumatol; 2021 Feb; 73(2):255-264. PubMed ID: 32783382
[TBL] [Abstract][Full Text] [Related]
13. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
Schwarting A; Relle M; Meineck M; Föhr B; Triantafyllias K; Weinmann A; Roth W; Weinmann-Menke J
Lupus; 2018 Feb; 27(2):243-256. PubMed ID: 28659046
[TBL] [Abstract][Full Text] [Related]
14. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
15. BAFF and selection of autoreactive B cells.
Liu Z; Davidson A
Trends Immunol; 2011 Aug; 32(8):388-94. PubMed ID: 21752714
[TBL] [Abstract][Full Text] [Related]
16. B-cell activating factor and related genetic variants in lupus related atherosclerosis.
Theodorou E; Nezos A; Antypa E; Ioakeimidis D; Koutsilieris M; Tektonidou M; Moutsopoulos HM; Mavragani CP
J Autoimmun; 2018 Aug; 92():87-92. PubMed ID: 29859654
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
18. Belimumab therapy in systemic lupus erythematosus.
Zouali M; Uy EA
BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
[TBL] [Abstract][Full Text] [Related]
19. The BAFF/APRIL system in SLE pathogenesis.
Vincent FB; Morand EF; Schneider P; Mackay F
Nat Rev Rheumatol; 2014 Jun; 10(6):365-73. PubMed ID: 24614588
[TBL] [Abstract][Full Text] [Related]
20. BAFF system expression in double negative 2, activated naïve and activated memory B cells in systemic lupus erythematosus.
Álvarez Gómez JA; Salazar-Camarena DC; Román-Fernández IV; Ortiz-Lazareno PC; Cruz A; Muñoz-Valle JF; Marín-Rosales M; Espinoza-García N; Sagrero-Fabela N; Palafox-Sánchez CA
Front Immunol; 2023; 14():1235937. PubMed ID: 37675114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
